Related Experiment Video
Updated: Aug 26, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Efficacy of Anakinra in Pericarditis: A Systematic Review
Ameer Haider Cheema1, Keyur Chaludiya1, Maham Khalid1
1Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Abstract:
Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching PubMed and GoogleScholar from the years 2012 to 2022. After applying inclusion and exclusion criteria, thorough screening, and quality appraisal, a total of eleven studies were included in the review; eight case reports and three clinical trials. All studies showed that 100 mg/day of anakinra caused a remarkable improvement in patient outcomes. In addition, the pericarditis resolved quicker and had a lower chance of recurrence in comparison to conventional therapy.
Related Concept Videos
Pericarditis III: Medical Management
Pericarditis I: Introduction
Pericarditis IV: Nursing Management
Pericarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

